1
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Antifungal Exposure and Resistance Development: Defining Minimal Selective Antifungal Concentrations and Testing Methodologies

      research-article

      Read this article at

          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          This scoping review aims to summarise the current understanding of selection for antifungal resistance (AFR) and to compare and contrast this with selection for antibacterial resistance, which has received more research attention. AFR is an emerging global threat to human health, associated with high mortality rates, absence of effective surveillance systems and with few alternative treatment options available. Clinical AFR is well documented, with additional settings increasingly being recognised to play a role in the evolution and spread of AFR. The environment, for example, harbours diverse fungal communities that are regularly exposed to antifungal micropollutants, potentially increasing AFR selection risk. The direct application of effect concentrations of azole fungicides to agricultural crops and the incomplete removal of pharmaceutical antifungals in wastewater treatment systems are of particular concern. Currently, environmental risk assessment (ERA) guidelines do not require assessment of antifungal agents in terms of their ability to drive AFR development, and there are no established experimental tools to determine antifungal selective concentrations. Without data to interpret the selective risk of antifungals, our ability to effectively inform safe environmental thresholds is severely limited. In this review, potential methods to generate antifungal selective concentration data are proposed, informed by approaches used to determine antibacterial minimal selective concentrations. Such data can be considered in the development of regulatory guidelines that aim to reduce selection for AFR.

          Related collections

          Most cited references120

          • Record: found
          • Abstract: found
          • Article: not found

          Hidden killers: human fungal infections.

          Although fungal infections contribute substantially to human morbidity and mortality, the impact of these diseases on human health is not widely appreciated. Moreover, despite the urgent need for efficient diagnostic tests and safe and effective new drugs and vaccines, research into the pathophysiology of human fungal infections lags behind that of diseases caused by other pathogens. In this Review, we highlight the importance of fungi as human pathogens and discuss the challenges we face in combating the devastating invasive infections caused by these microorganisms, in particular in immunocompromised individuals.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Simultaneous Emergence of Multidrug-Resistant Candida auris on 3 Continents Confirmed by Whole-Genome Sequencing and Epidemiological Analyses.

            Candida auris, a multidrug-resistant yeast that causes invasive infections, was first described in 2009 in Japan and has since been reported from several countries.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Mucormycosis in COVID-19: A systematic review of cases reported worldwide and in India

              Background and aims There are increasing case reports of rhino-orbital mucormycosis in people with coronavirus disease 2019 (COVID-19), especially in India. Diabetes mellitus (DM) is an independent risk factor for both severe COVID-19 and mucormycosis. We aim to conduct a systematic review of literature to find out the patient's characteristics having mucormycosis and COVID-19. Methods We searched the electronic database of PubMed and Google Scholar from inception until May 13, 2021 using keywords. We retrieved all the granular details of case reports/series of patients with mucormycosis, and COVID-19 reported world-wide. Subsequently we analyzed the patient characteristics, associated comorbidities, location of mucormycosis, use of steroids and its outcome in people with COVID-19. Results Overall, 101 cases of mucormycosis in people with COVID-19 have been reported, of which 82 cases were from India and 19 from the rest of the world. Mucormycosis was predominantly seen in males (78.9%), both in people who were active (59.4%) or recovered (40.6%) from COVID-19. Pre-existing diabetes mellitus (DM) was present in 80% of cases, while concomitant diabetic ketoacidosis (DKA) was present in 14.9%. Corticosteroid intake for the treatment of COVID-19 was recorded in 76.3% of cases. Mucormycosis involving nose and sinuses (88.9%) was most common followed by rhino-orbital (56.7%). Mortality was noted in 30.7% of the cases. Conclusion An unholy trinity of diabetes, rampant use of corticosteroid in a background of COVID-19 appears to increase mucormycosis. All efforts should be made to maintain optimal glucose and only judicious use of corticosteroids in patients with COVID-19.
                Bookmark

                Author and article information

                Contributors
                Journal
                Front Fungal Biol
                Front Fungal Biol
                Front. Fungal Biol.
                Frontiers in Fungal Biology
                Frontiers Media S.A.
                2673-6128
                13 June 2022
                2022
                : 3
                : 918717
                Affiliations
                [1] 1 European Centre for Environment and Human Health, University of Exeter Medical School , Cornwall, United Kingdom
                [2] 2 Environment and Sustainability Institute, University of Exeter Medical School , Cornwall, United Kingdom
                [3] 3 Medical Research Council Centre for Medical Mycology, University of Exeter , Exeter, United Kingdom
                [4] 4 Chief Scientist’s Group, Environment Agency, Horizon House , Bristol, England, United Kingdom
                Author notes

                Edited by: Robert T. Wheeler, University of Maine, United States

                Reviewed by: Renátó Kovács, University of Debrecen, Hungary; João Brandão, Instituto Nacional de Saúde Doutor Ricardo Jorge (INSA), Portugal

                *Correspondence: Aimee K. Murray, a.k.murray@ 123456exeter.ac.uk

                This article was submitted to Fungal Pathogenesis, a section of the journal Frontiers in Fungal Biology

                Article
                10.3389/ffunb.2022.918717
                10512330
                37746188
                78584d15-9700-4f66-978d-90de3e9650d4
                Copyright © 2022 Stevenson, Gaze, Gow, Hart, Schmidt, Usher, Warris, Wilkinson and Murray

                This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

                History
                : 12 April 2022
                : 16 May 2022
                Page count
                Figures: 5, Tables: 1, Equations: 0, References: 120, Pages: 15, Words: 7899
                Categories
                Fungal Biology
                Hypothesis and Theory

                antifungal resistance,antifungals,antimicrobial resistance,experimental evolution,selection,minimal selective concentration,fungi

                Comments

                Comment on this article